Lonza Antharis Dual-Payload ADC License | Lucid Diligence Brief
Lonza and Antharis license dual-payload ADC technology for gastrointestinal…
Intravacc and SynphaBase Conjugate Vaccine Partnership | Lucid Diligence Brief
Can Intravacc and SynphaBase create a streamlined synthetic glycan-to-GMP…
GNI Group Acquires Ayumi Pharmaceutical | Lucid Diligence Brief
GNI Group’s Ayumi acquisition tests Japan commercial scale, Calonal durability,…
Stipple Bio’s Lonza ADC Deal | Lucid Diligence Brief
Stipple Bio’s Lonza ADC license raises the execution test for STP-100 and…
Rallybio Avenzo Merger and $215M Financing | Lucid Diligence Brief
Rallybio and Avenzo’s reverse merger puts Nasdaq access, $215M financing and…
Pfizer Innovent Oncology Deal | Lucid Diligence Brief
Pfizer Innovent Oncology Deal tests China-originated ADC and multi-specific…
Lucid Diligence Brief: SELLAS REGAL AML Phase 3 Nears Final Analysis
Lucid Diligence Brief: SELLAS approaches REGAL AML final analysis for…
Lucid Diligence Brief: Cullinan Therapeutics Gains FDA Orphan Drug Designation for CLN-049
Lucid Diligence Brief: Cullinan Therapeutics Receives FDA Orphan Drug…
Lucid Diligence Brief: Plus Therapeutics and Ephemeral AI Partnership in CNS Oncology
Lucid Diligence Brief: Plus Therapeutics and Ephemeral AI partnership raises…
Lucid Diligence Brief: Helio Genomics and Syneos Health Deal
Lucid Diligence Brief: Helio Genomics and Syneos Health Deal to expand…
Lucid Diligence Brief: NeuroVision’s Durin Life Sciences acquisition
Lucid Diligence Brief: NeuroVision’s Durin Life Sciences acquisition…
Lucid Diligence Brief: Roche to acquire PathAI
Lucid Diligence Brief: Roche acquires PathAI for USD 1.05B to advance AI…